Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antibiotics Legislation Could Boost Confidence Of Sponsors And FDA Alike

Executive Summary

A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.


Related Content

Antibiotic Limited Use Claims Present Challenge Of Actually Limiting Use
Biomedical Reform Legislation Draft Could Be Released By January
To Revolutionize Antibiotic Pipeline Start With Rapid Diagnostics
To Revolutionize Antibiotic Pipeline Start With Rapid Diagnostics
Antibiotic Development Incentives Face Critical Test As NDA Reviews Begin
CDC’s Antibiotic-Resistance Battle Plan Emphasizes Preserving Current Drugs
Antibiotics For Drug-Resistant Infections Hope To Skip Phase III Trials
Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain
Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity
Ketek Act I: FDA Updates Label, Touts Process On Eve Of Hearing


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts